caus
emerg
human
coronaviru
becom
global
pandem
lead
seriou
threat
human
health
far
none
vaccin
specif
antivir
drug
approv
therapeut
antibodi
obtain
hyper
immun
equin
plasma
studi
herein
rbd
gram
level
obtain
chines
hamster
ovari
cell
highdens
ferment
bind
rbd
receptor
human
verifi
efficaci
rbd
vivo
test
mice
hors
result
rbd
trigger
hightit
neutral
antibodi
vivo
immunoglobulin
fragment
f
ab
prepar
hors
antisera
remov
fc
neutral
test
demonstr
rbdspecif
f
ab
inhibit
show
potent
inhibitori
effect
result
highlight
rbdspecif
f
ab
therapeut
candid
recent
year
emerg
remerg
virus
sever
acut
respiratori
syndromecoronaviru
sarscov
ebola
lassa
zika
influenza
middl
east
respiratori
syndromecoronaviru
merscov
other
challeng
global
biosafeti
system
attract
high
attent
world
firstli
identifi
wuhan
china
lead
coronaviru
diseas
covid
caus
global
pandem
million
confirm
case
thousand
death
averag
fatal
countri
world
peak
outbreak
human
suffer
risk
infect
unfortun
vaccin
drug
approv
clinic
use
spite
alreadi
clinic
trial
chloroquin
remdesivir
epidem
situat
urgent
call
effect
specif
quickli
access
drug
neutral
antibodi
nab
play
import
role
antivir
benefit
effect
inhibit
virus
entri
stage
prevent
viral
attach
membran
fusion
polyclon
antibodi
convalesc
plasma
recov
patient
usual
made
emerg
treatment
emerg
infecti
diseas
howev
lack
blood
sourc
risk
bloodborn
diseas
imped
wide
clinic
applic
convalesc
plasma
antisera
produc
larg
anim
like
hors
passiv
immun
provid
altern
commerci
process
obtain
hors
antiserum
deriv
matur
modern
pharmaceut
industri
know
report
employ
angiotensin
convert
enzym
enter
host
cell
use
receptor
sarscov
note
amino
acid
sequenc
ident
sarscov
spike
protein
protein
consist
respons
receptor
attach
respons
membran
fusion
receptor
bind
domain
rbd
sarscov
could
potent
induc
nab
vivo
thu
rbd
theoret
good
immunogen
motiv
nab
vivo
base
rbd
express
mammalian
cell
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
antigen
efficaci
test
mice
hors
use
tradit
system
immun
immunogen
doseincreas
strategi
rbd
elicit
hightit
nab
hors
f
ab
acquir
remov
fc
igg
efficaci
evalu
neutral
test
live
viru
vitro
f
ab
report
valid
efficaci
rbd
trigger
nab
vivo
highlight
altern
immunotherapi
aim
effect
elicit
nab
without
trigger
unrel
antibodi
vivo
rbd
select
immunogen
rather
fulllength
protein
inactiv
whole
viru
viruslik
particl
gene
obtain
de
novo
synthesi
codon
optim
rbd
express
plasmid
construct
describ
fig
get
larg
amount
rbd
protein
plasmid
transfect
cho
cell
follow
highdens
ferment
rbdfc
protein
secret
medium
purifi
affin
chromatographi
protein
consid
fc
tag
may
induc
unexpect
antibodi
vivo
complet
remov
fc
thrombin
digest
conduct
repeat
purif
protein
remov
residu
fc
base
method
gramlevel
rbd
protein
obtain
examin
valid
rbd
produc
studi
character
size
puriti
bind
capac
receptor
human
fig
singl
strip
observ
lane
rbdfc
rbd
detect
reduc
sdspage
impli
high
puriti
recombin
protein
bind
activ
rbd
human
overexpress
surfac
hela
cell
determin
flow
cytometri
contrast
rbd
bound
hela
cell
transient
transfect
human
plasmid
rare
bound
hela
cell
overexpress
fig
furthermor
cellular
receptor
block
experi
rbd
inhibit
entri
dose
depend
manner
fig
result
demonstr
structur
valid
rbd
prepar
studi
guarante
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
avail
research
rbd
first
test
mice
examin
effect
trigger
antibodi
respons
vivo
accord
tradit
immun
scheme
describ
method
section
mice
immun
mous
via
subcutan
inject
freund
adjuv
shown
fig
mice
immun
three
time
total
twoweek
interv
sera
sampl
adopt
ten
day
immun
monitor
antibodi
respons
fig
titer
specif
antibodi
rbd
detect
antigencaptur
elisa
titer
elev
immun
time
reach
third
immun
reflect
rbd
effect
elicit
antibodi
mice
neutral
test
sera
rbdimmun
mice
second
immun
inhibit
dilut
sera
third
immun
inhibit
dilut
show
immun
timesdepend
fig
sera
rbdimmun
mice
second
immun
third
immun
achiev
respect
inhibit
sera
rbdimmun
mice
third
immun
also
confirm
indirect
immunofluoresc
analysi
infect
cell
sharpli
reduc
decreas
sera
dilut
shown
fig
show
similar
tendenc
fig
result
collect
demonstr
rbd
could
use
immunogen
trigger
nab
vivo
base
rbd
taken
immunogen
produc
hors
antisera
hors
immun
rbd
complet
freund
adjuv
first
time
incomplet
freund
adjuv
subsequ
time
via
intramuscular
inject
amount
rbd
doubl
first
three
time
mg
mg
hors
fix
mg
per
hors
boost
plasma
collect
fig
sera
adopt
routin
immun
monitor
antibodi
respons
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
consequ
titer
specif
antibodi
increas
immun
time
reach
third
immun
fig
sera
second
third
immun
put
high
neutral
fig
correspond
infect
cell
less
treatment
sera
third
immun
dilut
infect
less
treatment
sera
dilut
fig
immun
strategi
describ
studi
hightit
neutral
sera
obtain
made
avail
antibodi
prepar
comparison
plasma
sampl
randomli
adopt
patient
wuhan
china
recov
februari
test
way
hors
antisera
result
plasma
sampl
inhibit
dilut
plasma
sampl
inhibit
dilut
plasma
sampl
inhibit
need
dilut
fig
hors
antisera
third
immun
inhibit
dilut
fig
demonstr
passiv
immun
hors
rbd
effici
produc
nab
purifi
antibodi
convalesc
plasma
natur
infect
impli
necess
produc
hors
antiseraderiv
antibodi
pepsin
digest
purif
describ
method
section
f
ab
obtain
hors
antisera
set
neutral
test
f
ab
found
inhibit
fig
shown
fig
inhibit
treatment
f
ab
inhibit
inhibit
observ
appar
dosedepend
manner
furthermor
kinet
bind
dissoci
recombin
rbd
determin
biomolecular
interact
analysi
kd
total
f
ab
rbd
nm
fig
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
improv
neutral
activ
f
ab
high
binder
rbd
purifi
total
f
ab
affin
chromatographi
rbd
neutral
activ
rbdspecif
f
ab
test
way
total
f
ab
expect
rbdspecif
f
ab
neutral
respect
fig
show
strong
inhibitori
effect
correspondingli
high
affin
rbdspecif
f
ab
rbd
reflect
kd
nm
fig
correl
neutral
activ
affin
rbd
suggest
f
ab
produc
studi
target
rbd
work
potent
neutral
potenti
f
ab
altern
vero
hela
cell
maintain
dulbecco
modifi
eagl
medium
gene
rbd
aa
synthes
genscript
co
ltd
clone
eukaryot
express
plasmid
pcagg
obtain
pcaggssign
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
collect
flowthrough
faction
affin
chromatographi
protein
repeatedli
conduc
complet
remov
residu
fc
rbdfc
rbd
analyz
sdspage
coomassi
brilliant
blue
stain
verifi
size
puriti
rbdfc
rbd
prepar
studi
reduc
sdspage
employ
reduc
sampl
prepar
mix
protein
load
buffer
ad
boil
water
minut
sampl
concentr
sdspage
separ
sdspage
final
sdspage
gel
stain
coomassi
brilliant
blue
imag
gel
decolour
captur
chemidoc
mp
imag
system
biorad
bind
rbd
human
detect
flow
cytometri
describ
elsewher
hela
cell
seed
plate
overnight
transfect
hela
cell
invitrogen
made
control
hour
later
cell
scrape
wash
pb
rbd
label
biotin
dialyz
pb
remov
residu
biotin
use
biotin
labelledrbd
ad
cell
mock
cell
final
concentr
incub
minut
cell
wash
pb
pe
streptavidin
bd
bioscienc
ca
usa
ad
cell
incub
minut
cell
wash
suspend
pb
detect
cytometri
bd
inhibit
entri
rbd
protein
carri
previous
describ
modif
cell
seed
plate
x
cellswel
overnight
remov
cultur
medium
rbd
dilut
fbsdmem
incub
cell
hour
pb
made
control
protein
remov
cell
wash
twice
pb
fbsdmem
ad
well
incub
hour
supernat
complet
remov
cell
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
wash
twice
pb
ad
fresh
fbsdmem
hour
later
cell
supernat
collect
viral
copi
detect
infect
calcul
control
femal
balbc
mice
age
week
hous
specif
pathogenfre
anim
care
facil
accord
homogen
primeboostboost
protocol
immun
perform
three
time
total
twoweek
interv
detail
rbd
volum
pb
mix
freund
complet
adjuv
four
healthi
hors
age
year
old
quarantin
inspect
hous
standard
breed
condit
immun
mg
rbd
protein
ml
pb
mix
equalvolum
freund
complet
adjuv
sigmaaldrich
prime
mg
rbd
protein
ml
pb
mix
equalvolum
freund
incomplet
adjuv
sigmaaldrich
first
boost
mg
rbd
protein
ml
pb
mix
equalvolum
freund
incomplet
adjuv
sigmaaldrich
second
boost
hors
homogen
receiv
intramuscular
inject
day
serum
sampl
collect
jugular
vein
day
monitor
variat
antibodi
respons
larg
amount
plasma
collect
collect
third
boost
collect
conduct
day
boost
mg
rbd
hors
recombin
rbd
protein
dilut
coat
plate
overnight
liquid
aspir
plate
wash
three
time
tween
block
nonfatmilk
hour
gradient
dilut
mous
hors
sera
ad
well
incub
room
temperatur
hour
pb
irrelev
sera
use
control
liquid
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
aspir
plate
wash
five
time
tween
incub
secondari
antibodi
conjug
hrp
room
temperatur
hour
wash
five
time
usual
ad
chromogen
reaction
termin
ad
minut
later
final
absorb
nm
measur
micropl
reader
tecan
swiss
valu
greater
twice
control
consid
posit
cell
seed
plate
x
cellswel
overnight
mous
hors
sera
human
convalesc
plasma
f
ab
firstli
dilut
fbsdmem
incub
hour
cell
supernat
aspir
antiseraor
antibodyviru
mixtur
ad
incub
hour
supernat
complet
remov
cell
wash
pb
supplement
fresh
fbsdmem
hour
cell
supernat
collect
subject
viral
rna
isol
cell
kept
indirect
immunofluoresc
analysi
viral
genom
copi
detect
qrtpcr
primer
target
gene
cell
plate
collect
viru
neutral
test
cell
wash
pb
fix
paraformaldehyd
permeabil
triton
cell
block
nonfatmilk
room
temperatur
hour
wash
pb
incub
rabbit
antinp
antibodi
room
temperatur
hour
cell
wash
incub
goat
antirabbit
alexa
fluor
antibodi
room
temperatur
hour
final
cell
wash
stain
dapi
minut
room
temperatur
imag
captur
fluoresc
microscop
olympu
japan
neutral
titer
hors
antisera
met
requir
plasma
collect
use
plasma
collect
machin
day
boost
briefli
plasma
firstli
dilut
bidistil
water
ratio
ph
adjust
hcl
pepsin
sigma
ad
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
temperatur
adjust
incub
preserv
hour
stir
pepsin
inactiv
temperatur
evalu
ammonium
sulfat
gradient
concentr
ad
proper
order
follow
filtrat
final
supernat
subject
protein
column
remov
residu
igg
f
ab
collect
flowthrough
fraction
affin
f
ab
rbd
monitor
biolay
interferometri
bli
use
octetr
devic
pall
fortebio
llc
ca
accord
previous
describ
protocol
briefli
rbd
biotinyl
room
temperatur
hour
incub
biotin
molar
ratio
residu
biotin
remov
dialysi
pb
biotinyl
rbd
load
onto
streptavidin
biosensor
fortebio
satur
f
ab
rbdspecif
f
ab
dilut
nm
nm
load
kinet
associ
kon
dissoci
kdi
measur
data
process
octet
data
analysi
system
purif
rbdspecif
f
ab
rbd
protein
express
cho
cell
prepar
describ
coupl
preactiv
resin
pabpursulfolink
bead
smart
life
scienc
changzhou
amino
reaction
rbdcoupl
resin
use
purifi
rbdspecif
f
ab
total
f
ab
brief
total
f
ab
dilut
mm
phosphat
buffer
ph
repeatedli
flow
rbdcoupl
resin
make
bind
rbd
resin
adequ
wash
mm
phosphat
buffer
ph
ad
glycin
elut
high
binder
elut
compon
rbdspecif
f
ab
dialyz
pb
remov
glycin
maintain
pb
use
show
hors
immunoglobulin
fragment
f
ab
potenti
provid
protect
clinic
evid
show
latent
period
short
day
week
patient
appear
recov
within
short
time
persist
latent
infect
organ
reason
conclud
neutral
antibodi
may
play
import
role
prevent
infect
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
mice
prove
inactiv
vaccin
induc
specif
antibodi
sarscov
neutral
test
vitro
also
prove
induc
antibodi
could
neutral
sarscov
major
problem
merit
studi
induct
neutral
antibodi
inactiv
sarscov
whole
viru
neutral
antibodi
may
enhanc
infect
coronaviru
sever
studi
show
antibodydepend
enhanc
ade
sar
coronaviru
infect
addit
report
antibodi
induc
enhanc
infect
found
studi
hiv
siv
dengu
viru
thu
spike
protein
receptor
bind
domain
rbd
select
immunogen
studi
could
induc
highli
effect
neutral
antibodi
higher
safeti
addit
rbdspecif
hors
f
ab
rel
specif
antibodi
uniqu
advantag
contrast
monoclon
antibodi
human
immunoglobulin
natur
infect
specif
target
rbd
prevent
bind
viru
receptor
bring
risk
associ
fc
avoid
ade
meanwhil
bind
multipl
epitop
rbd
hint
broadspectrum
neutral
human
bat
sarsrel
coronavirus
bat
sarslik
coronavirus
furthermor
demonstr
neutral
titer
hors
antisera
immun
rbd
higher
convalesc
human
plasma
natur
infect
studi
moreov
hors
could
immun
time
higher
titer
therapeut
antibodi
obtain
hyper
immun
equin
plasma
expect
studi
larg
amount
hors
antisera
prepar
immun
rbd
make
rbd
immunogen
verifi
conform
receptor
bind
experi
test
antigen
mice
accord
strategi
immunogen
doseincreas
strategi
hightit
hors
antisera
obtain
f
ab
manufactur
gmp
workshop
process
clinic
studi
matter
fact
monoclon
antibodi
sarscov
like
potent
bind
neutral
verifi
neutral
antibodi
sarscov
prove
weakli
bind
rbd
f
ab
prepar
studi
potenti
neutral
sarscov
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
extent
sinc
contain
antibodi
bind
multipl
epitop
rbd
addit
amino
acid
sequenc
ident
sarscov
rbd
two
employ
receptor
enter
host
cell
besid
f
ab
kind
immunoglobulin
fragment
prepar
remov
fc
igg
retain
activ
fragment
significantli
reduc
side
effect
bodi
although
hors
f
ab
heterolog
protein
human
immun
system
hors
serum
protein
fcrelat
protein
remov
much
possibl
use
modern
industri
techniqu
also
singledos
administr
avoid
advers
effect
efficaci
fall
induc
repeat
administr
addit
oper
fc
remov
elimin
major
concern
ade
coronavirus
enabl
antibodi
drug
hors
f
ab
candid
therapi
summari
herein
success
obtain
therapeut
antibodi
hyper
immun
equin
plasma
hors
immunoglobulin
fragment
f
ab
rbd
highlight
potenti
therapeut
studi
financi
support
grant
nation
ministri
scienc
technolog
emerg
project
hubei
provinci
depart
scienc
technolog
emerg
project
studi
also
support
wuhan
nation
biosafeti
laboratori
chines
academi
scienc
would
like
thank
ding
gao
juan
min
centr
instrument
analysi
metrolog
wuhan
institut
virolog
chines
academi
scienc
provid
technic
assist
also
thank
staff
wuhan
institut
virolog
chines
academi
scienc
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
sera
rbdimmun
mice
detect
set
neutral
test
live
cell
sera
dilut
shown
figur
mark
green
line
inhibit
sera
rbdimmun
mice
third
immun
detect
ifa
sera
dilut
use
neutral
test
infect
cell
detect
antibodi
target
np
cell
nucleus
stain
dapi
bright
field
merg
one
also
includ
venou
blood
adopt
day
immun
monitor
antibodi
respons
plasma
collect
mg
rbd
immun
usual
b
titer
specif
antibodi
hors
sera
immun
examin
rbdcaptur
elisa
c
sera
rbdimmun
hors
examin
neutral
test
live
cell
sera
dilut
shown
figur
mark
green
line
inhibit
sera
rbdimmun
hors
third
immun
detect
ifa
sera
dilut
use
neutral
test
infect
cell
detect
antibodi
target
np
cell
nucleus
stain
dapi
bright
field
merg
one
also
includ
e
inhibit
convalesc
plasma
detect
neutral
test
cell
usual
plasma
randomli
adopt
convalesc
patient
wuhan
plasma
dilut
shown
figur
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
ifa
np
work
concentr
f
ab
c
affin
f
ab
rbd
detect
bli
kinet
kon
kdi
process
octet
data
analysi
system
bind
curv
obtain
pass
f
ab
concentr
nm
biotinyl
rbd
immobil
streptavidin
biosensor
surfac
kinet
valu
kd
calcul
deduct
baselin
fit
associ
dissoci
respons
langmuir
bind
model
